Current Colorectal Cancer Reports

, Volume 9, Issue 4, pp 391–397 | Cite as

Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer

  • Sandip P. PatelEmail author
  • Takuya Osada
  • Koya Osada
  • Herbert Hurwitz
  • H. Kim Lyerly
  • Michael A. Morse
Immunotherapy of Malignancy (MA Morse, Section Editor)


T cell infiltration of colorectal cancer is associated with improved clinical outcome, underlining the importance of the immune system in cancer control; however, immune checkpoints, including the inhibitory T cell molecules CTLA-4 and PD-1 that temper the native immune response, mitigating autoimmunity, are coopted by tumors to facilitate escape from immune surveillance. Blockade of CTLA-4 and PD-1 and its ligand PD-L1, expressed by many tumors, have shown impressive activity in melanoma, renal cell carcinoma, and lung cancer. Immune checkpoint inhibition has been less well studied in colorectal cancer, but preclinical and clinical investigations are in progress.


Colorectal cancer Immune checkpoint CTLA-4 PD-1 PD-L1 mCRC Immunomodulation Vaccine Colon cancer Ipilimumab Tremelimumab Nivolumab Lambrolizumab 


Compliance with Ethics Guidelines

Conflict of Interest

Sandip P. Patel declares that he has no conflict of interest. Takuya Osada declares that he has no conflict of interest. Koya Osada declares that he has no conflict of interest. Herbert Hurwitz has received compensation for service as a consultant and is supported by grants from Roche, Genentech, Bristol-Myers Squibb, Sanofi-Aventis, Amgen, Regeneron, Novartis, TRACON, and Threshold Pharmaceuticals. H. Kim Lyerly declares that he has no conflict of interest. Michael A. Morse is supported be a grant from Bristol-Myers Squibb, and has received payment for lectures including service on speakers bureaus from Genentech.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Sandler A, Gray R, Ph D, et al.. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. 2006; 2542-2550Google Scholar
  4. 4.
    Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer. 2012;11:1–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Pagès F, Galon J, Dieu-Nosjean M-C, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102.PubMedCrossRefGoogle Scholar
  6. 6.
    Osada T, Hsu D, Hammond S, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody. Br J Cancer. 2009;102:124–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28:4045–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Ellebaek E, Andersen MH, Svane IM, et al. Immunotherapy for metastatic colorectal cancer: Present status and new options. Scand j gastroenterol. 2012;47:315–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Boghossian S, Robinson S, Von Delwig A, et al. Immunotherapy for treating metastatic colorectal cancer. Surg Oncol. 2012;21:67–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med 0:nullGoogle Scholar
  12. 12.
    Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 0:nullGoogle Scholar
  13. 13.
    •• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. Large phase 1 trial assessing anti-PD-1 and establishment of PD-L1 on tumor as putative predictive biomarker for response.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366:2455–65. Large phase 1 trial assessing anti-PD-L1 therapy.PubMedCrossRefGoogle Scholar
  15. 15.
    Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. Clin Cancer Res. 2012;18:2039–47.PubMedCrossRefGoogle Scholar
  16. 16.
    Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci. 1999;96:185–90.PubMedCrossRefGoogle Scholar
  17. 17.
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. Excellent review of basic biology of immune checkpoints and translational development of immune checkpoint inhibitors.PubMedCrossRefGoogle Scholar
  18. 18.
    Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J exp med. 2009;206:1717–25.PubMedCrossRefGoogle Scholar
  19. 19.
    Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J exp med. 2006;203:883–95.PubMedCrossRefGoogle Scholar
  22. 22.
    Francisco LM, Salinas VH, Brown KE, et al.: PD-L1 regulates the development , maintenance , and function of induced regulatory T cells. 206:3015–3029, 2009Google Scholar
  23. 23.
    Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci. 2010;107:4275–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–45.PubMedCrossRefGoogle Scholar
  25. 25.
    Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. nature. 2005;439:682–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.PubMedCrossRefGoogle Scholar
  27. 27.
    Blank C, Gajewski T, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.PubMedCrossRefGoogle Scholar
  28. 28.
    Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56:739–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99:12293–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci. 2007;104:3360–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757–66.PubMedCrossRefGoogle Scholar
  32. 32.
    Mu C-Y, Huang J-A, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. Cancer Res. 2006;66:3381–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Ogino S, Nosho K, Irahara N, et al. Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype. Clin Cancer Res. 2009;15:6412–20.PubMedCrossRefGoogle Scholar
  36. 36.
    Pagès F, Berger A, Camus M, et al. Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. N Engl J Med. 2005;353:2654–66.PubMedCrossRefGoogle Scholar
  37. 37.
    • Pagès F, Kirilovsky A, Mlecnik B, et al. In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer. J Clin Oncol. 2009;27:5944–51. Development of prognostic immunoscore assessing effector and memory T cells within colorectal tumor specimens which are associated with improved prognosis.PubMedCrossRefGoogle Scholar
  38. 38.
    Naito Y, Saito K, Shiiba K, et al. CD8+ T Cells Infiltrated within Cancer Cell Nests as a Prognostic Factor in Human Colorectal Cancer. Cancer Res. 1998;58:3491–4.PubMedGoogle Scholar
  39. 39.
    Salama P, Phillips M, Grieu F, et al. Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J Clin Oncol. 2009;27:186–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody. Clin Cancer Res. 2009;15:5379–88.PubMedCrossRefGoogle Scholar
  41. 41.
    Kocak E, Lute K, Chang X, et al. Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity. Cancer Res. 2006;66:7276–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer res. 2005;65:1089–96.PubMedGoogle Scholar
  43. 43.
    Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat med. 2002;8:793–800.PubMedCrossRefGoogle Scholar
  44. 44.
    M. Grimm MG, M. Koenigshausen, C. Stein, J. Lutz, S. Krol, A. Thiede, U. Heemann and A. Waaga-Gasser: Abstract: Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer. J Clin Oncol 26;:suppl 15005 (ASCO Meeting Abstracts), 2008Google Scholar
  45. 45.
    Terme M, Ullrich E, Aymeric L, et al. IL-18 Induces PD-1–Dependent Immunosuppression in Cancer. Cancer Res. 2011;71:5393–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int immunol. 2005;17:133–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Yu P, Steel JC, Zhang M, et al. Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model. Clin Cancer Res. 2010;16:6019–28.PubMedCrossRefGoogle Scholar
  48. 48.
    Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer res. 2011;71:3540–51.PubMedCrossRefGoogle Scholar
  49. 49.
    Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–94.PubMedCrossRefGoogle Scholar
  50. 50.
    Tel J, Hato SV, Torensma R, et al. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012;61:1101–11.PubMedCrossRefGoogle Scholar
  51. 51.
    Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J clin investig. 2011;121:3100.PubMedCrossRefGoogle Scholar
  52. 52.
    Pander J, Heusinkveld M, van der Straaten T, et al. Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. Clin Cancer Res. 2011;17:5668–73.PubMedCrossRefGoogle Scholar
  53. 53.
    Pander J, Gelderblom H, Antonini NF, et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur j cancer (Oxford, England : 1990). 2010;46:1829–34.CrossRefGoogle Scholar
  54. 54.
    Simon Pernot MT, Marcheteau E, Voron T, Colussi O, Tartour E, Taïeb J. Impact of antiangiogenic treatments on exhausted PD-1+ T lymphocytes in colorectal cancer. J Clin Oncol, 2013Google Scholar
  55. 55.
    Petty JK, He K, Corless CL, et al. Survival in human colorectal cancer correlates with expression of the T cell costimulatory molecule OX-40 (CD134). Am J Surg. 2002;183:512–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Pan PY, Zang Y, Weber K, et al. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 2002;6:528–36.PubMedCrossRefGoogle Scholar
  57. 57.
    Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse Model. J Natl Cancer Inst. 2000;92:931–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Yang JC, Hughes M, Kammula U, et al. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis. J Immunother. 2007;30:825–30. doi: 10.1097/CJI.0b013e318156e47e.PubMedCrossRefGoogle Scholar
  59. 59.
    Lynch T, Bondarenko I, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28:7531.CrossRefGoogle Scholar
  60. 60.
    NCT01769222: Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer (Phase 1/2).Google Scholar
  61. 61.
    Chung KY, Gore I, Fong L, et al. Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer. J Clin Oncol. 2010;28:3485–90.PubMedCrossRefGoogle Scholar
  62. 62.
    •• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. Excellent overview of the novel immune response criteria and definitions of progression related to all immunotherapeutics.PubMedCrossRefGoogle Scholar
  63. 63.
    •• Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388–97. Comprehensive overview of the pitfalls of classical clinial trial design and statistical criteria in evaluating immunotherapy.PubMedCrossRefGoogle Scholar
  64. 64.
    Ribas A, Kefford R, Marshall MA, et al. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. J Clin Oncol. 2013;31:616–22.PubMedCrossRefGoogle Scholar
  65. 65.
    Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sandip P. Patel
    • 1
    Email author
  • Takuya Osada
    • 1
  • Koya Osada
    • 1
  • Herbert Hurwitz
    • 1
  • H. Kim Lyerly
    • 1
  • Michael A. Morse
    • 1
  1. 1.Department of Medicine, Division of Medical OncologyDuke University Medical CenterDurhamUSA

Personalised recommendations